Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577272 | 0.93 | DRD2 (0.48) | ALDH1A1KDM4EHTTGFERMEN1 | |
| SCHEMBL5577352 | 0.92 | MEN1 (0.49) | ALDH1A1GFERMEN1KMT2AHDAC1 | |
| SCHEMBL5577828 | 0.89 | POLB (0.53) | ALDH1A1KDM4EMEN1KMT2AHDAC1 | |
| SCHEMBL5577876 | 0.88 | ALDH1A1 (0.65) | ALDH1A1KDM4EHTTGFERMEN1 | |
| SCHEMBL5577497 | 0.85 | DRD2 (0.58) | ALDH1A1KDM4EHTTMEN1KMT2A | |
| SCHEMBL5577744 | 0.83 | ABCB1 (0.49) | ALDH1A1KDM4EMCHR1SMN1; SMN2 | |
| SCHEMBL5577864 | 0.82 | ALDH1A1 (0.52) | ALDH1A1KDM4EHTTMEN1KMT2A | |
| SCHEMBL5577280 | 0.81 | MEN1 (0.59) | ALDH1A1KDM4EHTTMEN1KMT2A | |
| SCHEMBL5577622 | 0.81 | MEN1 (0.60) | ALDH1A1MEN1KMT2AHDAC1MCHR1 | |
| SCHEMBL5577475 | 0.80 | TSHR (0.62) | ALDH1A1KDM4EHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | ALDH1A1 1147/4885KDM4E 4213/4885HTT 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.